Chronic Disease Flexible Coverage Act
U.S. Congress · HR919 ·
Progression
Timing in context
Primary sponsor's contributions received (same period)
Adjacency in time is shown for context; it is not evidence of cause. Funded ≠ false — see the methodology.
What the bill says
Introduced 2025-02-04. Latest action: Received in the Senate and Read twice and referred to the Committee on Finance.
Summary (plain-language)
Chronic Disease Flexible Coverage Act This bill provides statutory authority for guidance from the Internal Revenue Service (IRS) that expands the types of preventive care that may be offered under a high deductible health plan (HDHP) without requiring a deductible or with a deductible below the minimum threshold. Under current law, to be considered health savings account-eligible, an HDHP must have a deductible above a certain minimum threshold amount, which is adjusted annually. However, an HDHP may cover certain types of preventive care without requiring a deductible or with a deductible below the minimum threshold. The IRS issued guidance expanding the types of preventive care that may be covered by an HDHP without requiring a deductible or with a deductible below the minimum threshold to include angiotensin converting enzyme inhibitors for individuals with congestive heart failure, diabetes, or coronary artery disease; anti-resorptive therapy for individuals with osteoporosis or osteopenia; beta-blockers for individuals with congestive heart failure or coronary artery disease; blood pressure monitors for individuals with hypertension; inhaled corticosteroids and peak flow meters for individuals with asthma; insulin and other glucose lowering agents, retinopathy screening, glucometers, and hemoglobin A1c testing for individuals with diabetes; international normalized ratio testing for individuals with liver disease or bleeding disorders; low-density lipoprotein testing for individuals with heart disease; statins for individuals with heart disease or diabetes; and selective serotonin reuptake inhibitors for individuals with depression. The bill provides statutory authority for the IRS's guidance.
Sponsors
- Vern Buchanan (primary)
- Jimmy Panetta
- Claudia Tenney
Text versions
What analysts say
No nonpartisan analysis on file for this measure yet.
What politicians say
No linked claims or utterances yet — no one on record has cited this measure to justify a public argument.
Action History
| Date | Action |
|---|---|
| 2025-03-05 | Received in the Senate and Read twice and referred to the Committee on Finance. |
| 2025-03-04 | Mr. Smith (MO) moved to suspend the rules and pass the bill. |
| 2025-03-04 | Considered under suspension of the rules. (consideration: CR H964-966) |
| 2025-03-04 | DEBATE - The House proceeded with forty minutes of debate on H.R. 919. |
| 2025-03-04 | Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964) |
| 2025-03-04 | On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H964) |
| 2025-03-04 | Motion to reconsider laid on the table Agreed to without objection. |
| 2025-02-04 | Introduced in House |
| 2025-02-04 | Referred to the House Committee on Ways and Means. |
Lobbying on this bill
Showing 18 of 18 bill mentions.
Honesty note: each filer below disclosed lobbying on this bill — that much the filing tells us. But the dollar figure is their total lobbying spend for the whole quarter across all their issues, not the amount spent on this bill, and the filing never says whether they supported or opposed it.
Source: Senate LDA filings.